[Page Banner Image]

The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.

The following information has been compiled from publicly available Sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.

Welcome back to the StratCom monthly update, hope you had a healthy and productive summer. The following are highlights of diagnostics related events that took place in July and August 2000.

This site is updated monthly, feel free to visit and contact us.

[HRule Image]

Molecular Biology — July and August 2000

The Institute for Genomic Research (TIGR) has published the genome sequence for the bacterium, Vibrio cholerae in the journal NATURE (Aug. 3, 2000). V. cholerae is the causative agent of cholera, an acute, diarrheal illness that most frequently occurs in epidemic form. Cholera remains a global plague. The genomic sequence of V. cholerae provides a model for the study of multi-chromosomal prokaryotic organisms, and will also provide important clues to understanding the metabolic and regulatory networks represented by genes linked on one or both the chromosomes.

AmeriPath, Inc. a physician and laboratory company focused on providing anatomic pathology, cancer diagnostic, and healthcare information services, has acquired MedGenetics Diagnostic Laboratories, a full-service cytogenetic practice devoted exclusively to clinical and laboratory genetic services. Terms of the acquisition were not disclosed.

Genomics One Corporation has entered into a five-year collaboration agreement with the University of British Columbia to create a complete bacterial artificial chromosome genomic library of the whooping cough agent, Bordetella pertussis. The B. pertussis genome currently being sequenced at the Sanger Centre in the UK. Genomics One will own the BAC library and the sequence data and UBC will own the results of the gene expression and identification studies.

Genzyme Molecular Oncology has issues a non-exclusive licensed to Myriad Genetics, Inc. its cancer diagnostic patent rights related to an undisclosed gene implicated in hereditary colon cancer. In September 2000, Myriad plans to launch a predictive medicine test for hereditary colon cancer called COLARIS that detects mutations in this gene and an additional gene that is not part of the license agreement.

Lynx Therapeutics, Inc. and Genomics Collaborative Inc. have formed a partnership to conduct a comprehensive genome-wide scan for single nucleotide polymorphisms, or SNPs, that are associated with type 2 diabetes, also known as non-insulin dependent diabetes mellitus. Genomics Collaborative will provide to Lynx over 4,000 DNA samples taken from type 2 diabetics and matched controls from the GCI's Global Repository.

[HRule Image]

* Molecular Biology - June 2000
* Molecular Biology - May 2000
* Molecular Biology - April 2000
* Molecular Biology - March 2000
* Molecular Biology - Febuary 2000
* Molecular Biology - January 2000
* Molecular Biology - December 1999
* Molecular Biology - November 1999
* Molecular Biology - October 1999
* Molecular Biology - September 1999

[HRule Image]

Home | Company Profile | Services | Research Reports Available
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links

[HRule Image]
Send mail to stratcom@pagebleu.com with questions or comments about this web site.

Concept and Design Blue Page Productions
Copyright © 1996-2000 STRATCOM

Last modified: September 01, 2000